Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma autologous eye drops
- Development stage
- Phase 3
- Lead developer
- Enrich Advanced Eye Care
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Topical, Ophthalmic
01
Overview
Platelet-rich plasma (PRP) autologous eye drops are a topical ophthalmic biologic therapy used for the treatment of severe dry eye disease and corneal damage. Developed as a clinical service by Enrich PRP (Enrich Advanced Eye Care), the drops are prepared from a patient's own blood, resulting in a 100% biological, preservative-free formulation. The preparation contains a high concentration of platelets that release essential growth factors—including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor beta (TGF-β), and Epidermal Growth Factor (EGF)—and cytokines to promote tissue repair, corneal epithelial healing, and nerve regeneration. Unlike standard autologous serum eye drops, PRP eye drops provide a more concentrated healing modality specifically suited for severe ocular surface disease where traditional therapies have failed.
- Other names
- PRP eye dropsautologous platelet-rich plasma eye dropsE-PRP eye dropsPlatelet-Rich Plasma Autologous Eye Drops
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TGFBR (TGF-beta receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on platelet-rich plasma autologous eye drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma autologous eye drops.